Tempus AI stock briefly jumped into a profit-taking zone Thursday after the Food and Drug Administration cleared its updated cardiac-imaging platform, Tempus Pixel.
The platform uses artificial intelligence to view cardiac magnetic resonance images, or MRI. Unlike conventional MR images that only show brightness differences, Tempus Pixel's maps provide precise numerical values to cardiac tissue characteristics. This helps clinicians detect conditions like fibrosis, inflammation or swelling that might otherwise go undetected.
Tempus Pixel can provide these images from raw MRI data, even if the scanner doesn't use the same platform.
"This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful," Chris DiVetta said in a written statement. DiVetta is Tempus' senior vice president of AI applications.
On today's stock market, Tempus AI stock surged 13.6% to 88.78. Earlier, shares hit 91.06, landing inside a profit-taking zone above a buy point of 74.83. Tempus shares broke out of a cup base on Aug. 15, according to MarketSurge. The profit-taking zone runs from 89.80 to 93.54.
Shares have a strong IBD Digital Relative Strength Rating of 92, putting them in the leading 8% of all stocks in terms of 12-month performance.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
